Combination/adjuvant therapy for wt-1-positive disease
AssigneeMemorial Sloan Kettering Cancer Center
InventorsDavid Scheinberg, Leonid Dubrovsky
Life of this patent
Estimating the term…
Abstract
In an attempt to improve primary disease responsiveness and/or to overcome resistant disease, the present disclosure provides a method for treating or inhibiting the proliferation of a WT-1-dependent cancer comprising providing to a subject in need thereof a therapeutically effective amount of a tyrosine kinase inhibitor along with an anti-WT-1/HLA antibody, that is, an antibody that specifically binds to a peptide of Wilms' tumor protein (WT-1) presented on the surface of the cancer cells in an HLA-restricted fashion.
Claims14
A method for treating or inhibiting the proliferation of a WT-1 positive cancer, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a tyrosine kinase inhibitor and a therapeutically effective amount of an anti-WT-1 antibody or antigen-binding fragment thereof.
The method of claim 5, wherein the pharmaceutically acceptable salt of imatinib is imatinib mesylate.
Dependencies are inferred from the claim text.